US › Healthcare

Lipocine Inc (LPCN)

US · Healthcare · Biotechnology

$1.56-7.14%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$190,099

Revenue YoY

-69.5%

Net profit

$-2.6M

EPS

$-0.32

EPS estimate

$-0.47

Net margin

-1,379.6%

EPS came in at -0.32 against a street estimate of -0.47 — a beat of 31.9%.

Key statistics

Market cap

$13.4M

Forward P/E

5.6

P/B

0.81

Book value

$2.64

EPS (TTM)

$-1.85

52-week high

$12.37

52-week low

$1.59

50-day MA

$2.14

200-day MA

$4.34

Beta

0.40

Analyst view

Analysts rate Lipocine Inc a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $5.00.

Shareholding

Insiders

4.96%

Institutions

36.19%

Largest institutional holders

Fund	Stake
Squadron Capital Management LLC	9.82%
Ikarian Capital, LLC	6.17%
Eversept Partners, LP	3.58%
Vanguard Capital Management, LLC	2.80%
Acadian Asset Management LLC	2.07%
BOOTHBAY FUND MANAGEMENT, LLC	1.70%
Jane Street Group LLC	1.16%
BlackRock Inc	1.08%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lipocine Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.